Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of FOLD
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Amicus Therapeutics stock price ended at $11.78 on Thursday, after losing 0.675%.
(Updated on Mar 28, 2024)

Sell candidate since Mar 12, 2024 Loss -0.08% PDF

The Amicus Therapeutics stock price fell by -0.675% on the last day (Thursday, 28th Mar 2024) from $11.86 to $11.78. During the last trading day the stock fluctuated 3.87% from a day low at $11.49 to a day high of $11.93. The price has been going up and down for this period, and there has been a 2.08% gain for the last 2 weeks. Volume has increased on the last day by 81 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $28.27 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -10.73% during the next 3 months and, with a 90% probability hold a price between $9.62 and $11.82 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

FOLD Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, March 26, 2024, and so far it has risen 3.06%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Amicus Therapeutics stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $12.66. On a fall, the stock will find some support from the short-term average at $11.69. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Amicus Therapeutics stock

Amicus Therapeutics finds support from accumulated volume at $11.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.445 between high and low, or 3.87%. For the last week, the stock has had daily average volatility of 3.46%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (FOLD) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect Amicus Therapeutics to open at $11.73, and during the day (based on 14 day Average True Range), to move between $11.32 and $12.24, which gives a possible trading interval of +/-$0.458 (+/-3.89%) up or down from last closing price. If Amicus Therapeutics takes out the full calculated possible swing range there will be an estimated 7.78% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $11.58 (1.70%) than the resistance at $12.43 (5.52%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Amicus Therapeutics stock A Buy?

Amicus Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -3.437 Sell Candidate Unchanged

Predicted Opening Price for Amicus Therapeutics of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$11.73 ( 0.410%) $11.78

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for FOLD

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 12.18 3.37 %
R2 12.01 1.92 %
R1 11.90 1.03 %
Current price: 11.78
Support S1 11.56 -1.85 %
S2 11.46 -2.74 %
S3 11.29 -4.19 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 13.53 14.86 %
R2 12.95 9.93 %
R1 12.43 5.52 %
Current price 11.78
Support S1 11.58 -1.70%
S2 11.54 -2.04%
S3 11.48 -2.55%

FAQ

What is the symbol for Amicus Therapeutics Stock and on which exchange is it traded?
The symbol for Amicus Therapeutics is FOLD and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Amicus Therapeutics Stock?
Amicus Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy Amicus Therapeutics Stock?
Amicus Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Amicus Therapeutics Stock.

What's the current price of Amicus Therapeutics Stock?
As of the end of day on the 2024-03-28, the price of an Amicus Therapeutics (FOLD) share was $11.78.

What is the 52-week high and low for Amicus Therapeutics Stock?
The 52-week high for Amicus Therapeutics Stock is $14.57 and the 52-week low is $9.70.

What is the market capitalization of Amicus Therapeutics Stock?
As of the 2024-03-28, the market capitalization of Amicus Therapeutics is 3.48B.

When is the next earnings date for Amicus Therapeutics?
The upcoming earnings date for Amicus Therapeutics is May 08, 2024.
Click to get the best stock tips daily for free!

About Amicus Therapeutics

Amicus Therapeutics Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym... FOLD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT